Discontinuation of odanacatib and other osteoporosis treatments: Here today and gone tomorrow?
@article{Bauer2011DiscontinuationOO, title={Discontinuation of odanacatib and other osteoporosis treatments: Here today and gone tomorrow?}, author={D. Bauer}, journal={Journal of Bone and Mineral Research}, year={2011}, volume={26} }
The options available for effective osteoporosis treatment continue to grow. Because of the large number of treatment options, many clinicians, particularly in primary care, are uncertain about when to start therapy, which drug to use, and when to stop. The issue of when to stop antifracture therapy is now front and center as evidence accumulates that the antifracture benefits of some treatments persist after discontinuation and as patients increasingly voice concerns about possible rare but… CONTINUE READING
Topics from this paper
19 Citations
Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures
- Medicine
- Osteoporosis International
- 2017
- 23
Clinical considerations for the use of antiresorptive agents in the treatment of metastatic bone disease.
- Medicine
- Critical reviews in oncology/hematology
- 2011
- 15
Cathepsin K osteoporosis trials, pycnodysostosis and mouse deficiency models: Commonalities and differences
- Medicine
- Expert opinion on drug discovery
- 2016
- 43
Teriparatide Therapy for Denosumab-Induced Osteonecrosis of the Jaw in a Male Osteoporotic Patient
- Medicine
- Calcified Tissue International
- 2014
- 17
Potential role of odanacatib in the treatment of osteoporosis
- Medicine
- Clinical interventions in aging
- 2012
- 34
- PDF
Implications of Osteoblast-Osteoclast Interactions in the Management of Osteoporosis by Antiresorptive Agents Denosumab and Odanacatib
- Chemistry, Medicine
- Current Osteoporosis Reports
- 2014
- 42
Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis
- Medicine
- Hormones
- 2011
- 23
- Highly Influenced
- PDF
Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation.
- Medicine
- BoneKEy reports
- 2012
- 72
- PDF
References
SHOWING 1-10 OF 16 REFERENCES
Fracture risk remains reduced one year after discontinuation of risedronate
- Medicine
- Osteoporosis International
- 2007
- 182
Safety of bisphosphonates in the treatment of osteoporosis.
- Medicine
- The American journal of medicine
- 2009
- 88
Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three‐year continued therapy and resolution of effect
- Medicine
- Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
- 2011
- 233
- Highly Influential
- PDF
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
- Medicine
- JAMA
- 2006
- 1,181
- Highly Influential
- PDF
Odanacatib, a cathepsin‐K inhibitor for osteoporosis: A two‐year study in postmenopausal women with low bone density
- Medicine
- Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
- 2010
- 310
- Highly Influential
Randomized Trial of Effect of Alendronate Continuation Versus Discontinuation in Women With Low BMD: Results From the Fracture Intervention Trial Long‐Term Extension
- Medicine
- Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
- 2004
- 247
- PDF
The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment of Osteoporosis: A Randomized Extension to the HORIZON-Pivotal Fracture Trial (PFT)
- Medicine
- Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
- 2012
- 463
- PDF
Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
- Medicine
- The Journal of clinical endocrinology and metabolism
- 2011
- 328
- PDF
Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double‐Blind, Randomized, Placebo‐Controlled Phase I Studies
- Medicine
- Clinical pharmacology and therapeutics
- 2009
- 143
- Highly Influential